68Ga-PSMA PET/CT 对初诊前列腺癌患者既往 99mTc 骨显像后骨转移检出的附加价值
本研究纳入 112 例初诊中高危前列腺癌患者,在 3 个月内先后行 99mTc 骨显像(BS)和 68Ga-PSMA-11 PET/CT,以最佳有效比较法为参考。68Ga-PSMA-11 PET/CT 灵敏度为 1.00、特异度为 0.93-0.96,在 BS 判为 M0 的患者中检出 8/81 例骨转移,在 BS 不确定的患者中为 20/22 例提供明确结果,但 4 例孤立肋骨病灶为假阳性。
要点
- 68Ga-PSMA-11 PET/CT 灵敏度 1.00、特异度 0.93-0.96、阳性预测值 0.74-0.81、阴性预测值 1.00。
- BS 判为 M0 的 81 例中,68Ga-PSMA-11 PET/CT 检出 8 例骨转移。
- BS 判为 M1 的 9 例,68Ga-PSMA-11 PET/CT 均确认骨转移。
核心结论
- 68Ga-PSMA-11 PET/CT 在 BS 无骨转移的患者中检出 10% 骨转移,在 BS 不确定患者中检出 36% 骨转移。
- 肋骨孤立 PSMA 高摄取病灶应谨慎解释,可能为假阳性。
研究设计与样本
- 纳入连续初诊中高危前列腺癌患者,均行 BS(多数辅以 SPECT/低剂量 CT)和 68Ga-PSMA-11 PET/CT,两次检查间隔小于 3 个月且期间未开始治疗。
- BS 按临床常规判读为无骨转移(M0)、骨转移(M1)或不确定(Me)。
- 68Ga-PSMA-11 PET/CT 由三名专家在患者水平盲法判读为 M0、M1 或 Me。
- 采用最佳有效比较法,以所有可用影像和临床随访为参考进行灵敏度分析。
主要发现
- 共纳入 112 例患者。
- 68Ga-PSMA-11 PET/CT 灵敏度 1.00、特异度 0.93-0.96、阳性预测值 0.74-0.81、阴性预测值 1.00。
- BS 判为 M0 的 81 例中,68Ga-PSMA-11 PET/CT 检出 8 例骨转移。
- BS 判为 M1 的 9 例,68Ga-PSMA-11 PET/CT 均确认骨转移。
- BS 判为 Me 的 22 例中,68Ga-PSMA PET/CT 为 20 例提供明确结果;4 例孤立肋骨病灶为假阳性。
关键数值与推荐
- 68Ga-PSMA-11 PET/CT 灵敏度 1.00、特异度 0.93-0.96、阳性预测值 0.74-0.81、阴性预测值 1.00。
- BS 判为 M0 的 81 例中 8 例经 68Ga-PSMA-11 PET/CT 检出骨转移(10%)。
- BS 判为 Me 的 22 例中 20 例经 68Ga-PSMA PET/CT 获得明确结果(36% 检出骨转移)。
- BS 判为 M1 的 9 例均经 68Ga-PSMA-11 PET/CT 确认骨转移。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the added value and diagnostic accuracy of 68Ga-PSMA PET/CT versus bone scintigraphy (BS) for bone metastasis detection at the primary staging of prostate cancer (PCa). METHODS: Inclusion criteria involved consecutive patients with newly diagnosed intermediate- to high-risk PCa, who had undergone BS, mostly with supplementary SPECT/low-dose CT, and 68Ga-PSMA-11 PET/CT within less than 3 months without therapy initiation between the two investigations. BS was evaluated according to clinical routine and reported as no bone metastases (M0), bone metastases (M1), or equivocal (Me). The 68Ga-PSMA-11 PET/CT was blindly evaluated by three specialists as M0, M1, or Me at the patient level. Sensitivity analyses were conducted using a "best valuable comparator" using all available imaging and clinical follow-up as a reference. RESULTS: In total, 112 patients were included; 68Ga-PSMA-11 PET/CT showed a sensitivity of 1.00, specificity of 0.93-0.96, positive predictive value of 0.74-0.81, and negative predictive value of 1.00. 68Ga-PSMA-11 PET/CT revealed bone metastases in 8 of 81 patients with M0 disease according to BS. 68Ga-PSMA-11 PET/CT confirmed the presence of bone metastases in all patients (n = 9) with M1 disease according to BS. In patients with Me by BS, 68Ga-PSMA PET/CT provided a definite result in 20 of 22 patients. 68Ga-PSMA-11 PET/CT resulted in a false-positive answer in four patients with solitary rib lesions. CONCLUSION: 68Ga-PSMA-11 PET/CT revealed bone metastases in 10% of patients without bone metastases on BS and in 36% patients with indeterminate BS. However, solitary PSMA-avid lesions in the ribs should be interpreted cautiously as they may represent false-positive findings.
引用
- Zacho HD, Ravn S, Afshar-Oromieh A, et al. Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res. 2020. PMID: 32270300. doi:10.1186/s13550-020-00618-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。